Latest stories on CANF
Can-Fite Biopharma GAAP EPS of -$1.24, revenue of $0.2M
Seeking Alpha28 · bearishearnings
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Yahoo Finance58 · neutralproduct/pr
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
GlobeNewswire28 · bearishgeneral
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
The Fly63 · neutralproduct/pr
Can-Fite Flags Longer Survival in Phase III Liver Cancer Trial, Eyes Earlier Interim Analysis
TipRanks67 · bullishproduct/pr
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
StockTitan58 · neutralproduct/pr
Can-Fite BioPharma files $100M mixed securities shelf
The Fly28 · bearishgeneral
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
StockTitan63 · neutralproduct/pr
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
StockTitan67 · bullishproduct/pr
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
StockTitan67 · bullishproduct/pr
Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson
TipRanks63 · neutralproduct/pr
Biggest stock movers Thursday: FIZZ, CANF, and more
Seeking Alpha50 · neutralgeneral
CANF Announces Phase 2a Results: Namodenoson Shows Durable Survival in Advanced Pancreatic Cancer
MarketChameleon67 · bullishproduct/pr
Why Is CANF Stock Surging Today?
Stocktwits News67 · bullishproduct/pr
Can-Fite’s Namodenoson Shows Durable Survival in Advanced Pancreatic Cancer Phase 2a Study—Primary Safety Endpoint Achieved
MarketChameleon67 · bullishproduct/pr
CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg Up
Stocktwits News56 · neutralproduct/pr
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology | CANF Stock News
StockTitan63 · neutralproduct/pr
Can-Fite BioPharma Showcases Broad Potential of A3AR Drug Platform in New Peer-Reviewed Study
TipRanks63 · neutralproduct/pr
Can-Fite BioPharma to Showcase Late-Stage Pipeline and Licensing Deals at BIO 2026
TipRanks56 · neutralproduct/pr